Literature DB >> 31648492

[Liver cancer epidemiology in China, 2015].

L An1, H M Zeng1, R S Zheng1, S W Zhang1, K X Sun1, X N Zou1, R Chen1, S M Wang1, X Y Gu2, W W Wei1, J He3.   

Abstract

Objective: Using updated population-based cancer registration (PBCR) data, we estimated nation-wide liver cancer statistics overall, by sex and by areas in China.
Methods: Qualified PBCR data of liver cancer in 2015 which met the data quality criteria were stratified by geographical locations, sex, and age groups. Age-specific incidence and mortality rates by sex and area were calculated. The burden of liver cancer was evaluated by multiplying these rates by the year of 2015 population. Chinese standard population in 2000 and World Segi's population were used for the calculation of age-standardized rates (ASR) of incidence and mortality.
Results: Qualified 368 cancer registries covered a total of 309 553 499 populations in China, accounting for 22.52% of the national population. It is estimated that there were 370 000 new cases (274 000 males and 96 000 females) of liver cancer in China. The age-standardized incidence rates by Chinese standard population (ASR China) and World Segi's population (ASR World) were 17.64 per 100 000 and 17.35 per 100 000, respectively. Rural areas showed higher incidence (ASR China: 20.07 per 100 000, ASR World: 19.67 per 100 000) than urban areas (ASR China: 15.90 per 100 000, ASR world: 15.67 per 100 000). Subgroup analysis showed that western areas of China had highest incidence rate of liver cancer, with the ASR China of 20.65 per 100 000 and 20.22 per 100 000 for ASR world, respectively. For new cases of liver cancer deaths, there were 326 000 new deaths (242 000 males and 84 000 females) in China, with age-standardized mortality rate by Chinese standard population and World Segi's population of 15.33 per 100 000 and 15.09 per 100 000, respectively. Rural areas showed higher mortality (ASR China: 17.17 per 100 000, ASR world: 16.86 per 100 000) than urban areas (ASR China: 14.00 per 100 000, ASR World: 13.81 per 100 000). Conclusions: There is still a heavy burden of liver cancer in China. Rural residents have higher incidence and mortality of liver cancer compared with urban counterparts. It is likely that many factors such as hepatitis virus infection, and aflatoxin exposure play a dominating role. Prevention and control strategies should be enhanced in the future.

Entities:  

Keywords:  Cancer registry; China; Incidence; Liver neoplasms; Mortality

Mesh:

Year:  2019        PMID: 31648492     DOI: 10.3760/cma.j.issn.0253-3766.2019.10.001

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  17 in total

1.  Umbilical cord blood-derived mesenchymal stem cells transplantation decreases incidence of liver cancer in end-stage liver disease patients: a retrospective analysis over 5 years.

Authors:  Le Luo; Chunyou Lai; Tianhang Feng; Yutong Yao; Hua Xue; Guangming Xiang; Lanyun Luo; Xiaolun Huang
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

2.  Clinical value of prophylactic transcatheter arterial chemoembolization treatment in patients with hepatocellular carcinoma.

Authors:  Hui Li; Zhihu Liu; Cuiping Han
Journal:  Am J Transl Res       Date:  2022-05-15       Impact factor: 3.940

3.  [Effect of ozone oil for prevention and treatment of sorafenib-induced hand-foot skin reactions: a randomized controlled trial].

Authors:  Xiaowei Chen; Yiyue Jiang; Ying Zhang; Wencong Dai; Rong Fan; Xie Weng; Peng He; Feifei Yan; Yabing Guo
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-10-30

4.  ApoM regulates PFKL through the transcription factor SREBF1 to inhibit the proliferation, migration and metastasis of liver cancer cells.

Authors:  Xiao Zhang; Yaping Bai; Wenhao Zhu; Xinyue Lv; Wenjun Pei
Journal:  Oncol Lett       Date:  2022-05-16       Impact factor: 3.111

5.  A Prognosis Marker Dynein Cytoplasmic 1 Heavy Chain 1 Correlates with EMT and Immune Signature in Liver Hepatocellular Carcinoma by Bioinformatics and Experimental Analysis.

Authors:  Yanhong Wang; Jiyu Han; Haichao Zhou; Songtao Ai; Daqian Wan
Journal:  Dis Markers       Date:  2022-05-11       Impact factor: 3.464

6.  Effects of FER1L4-miR-106a-5p/miR-372-5p-E2F1 regulatory axis on drug resistance in liver cancer chemotherapy.

Authors:  Xu Wang; Yunfei Chen; Ke Dong; Yujing Ma; Qizhi Jin; Shujun Yin; Xiaoshi Zhu; Shan Wang
Journal:  Mol Ther Nucleic Acids       Date:  2021-02-10       Impact factor: 8.886

7.  Berberine-10-hydroxy camptothecine-loaded lipid microsphere for the synergistic treatment of liver cancer by inhibiting topoisomerase and HIF-1α.

Authors:  Yingjie Qi; Guangxuan Liu
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

8.  Fibrinogen-like protein 2 promotes the accumulation of myeloid-derived suppressor cells in the hepatocellular carcinoma tumor microenvironment.

Authors:  Bo-Qian Liu; Zhi-Ye Bao; Jia-Yi Zhu; Hao Liu
Journal:  Oncol Lett       Date:  2020-11-17       Impact factor: 2.967

9.  Heat Shock Protein Beta 1 is a Prognostic Biomarker and Correlated with Immune Infiltrates in Hepatocellular Carcinoma.

Authors:  Shengyi Long; Fang Peng; Baohui Song; Liang Wang; Jun Chen; Bingbing Shang
Journal:  Int J Gen Med       Date:  2021-09-10

10.  Molecular mechanism of atractylon in the invasion and migration of hepatic cancer cells based on high‑throughput sequencing.

Authors:  Yang Cheng; Jian Ping; Jianjie Chen; Yifei Fu; Hui Zhao; Jiahua Xue
Journal:  Mol Med Rep       Date:  2022-02-04       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.